Hq Spclt Pharma Company Profile
What is the competitive landscape for HQ SPCLT PHARMA
HQ SPCLT PHARMA has fifteen approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
Summary for Hq Spclt Pharma
| US Patents: | 6 |
| Tradenames: | 18 |
| Ingredients: | 12 |
| NDAs: | 15 |
Drugs and US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | SOLUTION;INTRAVENOUS | 206628-003 | Jun 22, 2018 | RX | Yes | No | 9,717,796 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hq Spclt Pharma | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | SOLUTION;INTRAVENOUS | 206628-004 | Jun 22, 2018 | RX | Yes | No | 9,717,796 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hq Spclt Pharma | CALCIUM GLUCONATE IN SODIUM CHLORIDE | calcium gluconate | SOLUTION;INTRAVENOUS | 210906-003 | Jun 4, 2021 | RX | Yes | Yes | 10,130,646 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Hq Spclt Pharma | CEFAZOLIN SODIUM | cefazolin sodium | POWDER;INTRAVENOUS | 211413-002 | Mar 8, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Hq Spclt Pharma | MEROPENEM | meropenem | INJECTABLE;INJECTION | 210773-002 | Aug 16, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hq Spclt Pharma | MEROPENEM | meropenem | INJECTABLE;INJECTION | 210773-001 | Aug 16, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hq Spclt Pharma | MAGNESIUM SULFATE IN PLASTIC CONTAINER | magnesium sulfate | INJECTABLE;INJECTION | 207350-005 | Dec 6, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | PLATINOL | cisplatin | INJECTABLE;INJECTION | 018057-001 | Approved Prior to Jan 1, 1982 | 5,562,925 | ⤷ Start Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 4,177,263 | ⤷ Start Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-002 | Approved Prior to Jan 1, 1982 | 4,177,263 | ⤷ Start Trial |
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 5,562,925 | ⤷ Start Trial |
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 5,641,803 | ⤷ Start Trial |
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 6,096,331 | ⤷ Start Trial |
| Hq Spclt Pharma | TAXOL | paclitaxel | INJECTABLE;INJECTION | 020262-001 | Dec 29, 1992 | 6,150,398 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2017184188 | ⤷ Start Trial |
| Australia | 2014228155 | ⤷ Start Trial |
| Argentina | 108806 | ⤷ Start Trial |
| European Patent Office | 2948379 | ⤷ Start Trial |
| China | 105263809 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2014143845 | ⤷ Start Trial |
| European Patent Office | 3429574 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2666774 | 132020000000073 | Italy | ⤷ Start Trial | PRODUCT NAME: RELEBACTAM, OPZIONALMENTE IN FORMA DEL MONOIDRATO, IMIPENEM E CILASTATINA, OPZIONALMENTE NELLA FORMA DEL SALE SODICO(RECARBRIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1420, 20200217 |
| 0717738 | 12/2002 | Austria | ⤷ Start Trial | PRODUCT NAME: LINEZOLID; NAT. REGISTRATION NO/DATE: 1-24227 - 1-24230 20011009; FIRST REGISTRATION: GB PL 00032/0259 - PL 00032/0262 20010105 |
| 2603514 | 1990017-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF VABORBACTAM AND/OR SALT OR HYDRATE THEREOF, AND MEROPENEM AND/OR A SALT HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE.; REG. NO/DATE: EU/1/18/1334 20181122 |
| 2957286 | 122018000145 | Germany | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; REGISTRATION NO/DATE: EU/1/17/1179 20170719 |
| 2957286 | 2018C/047 | Belgium | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 2365988 | 2018C/006 | Belgium | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM OF EERDER WELK ZOUT OF AFGELEIDE ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 1853250 | 300673 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
